Last kr179.00 SEK
Change Today +3.50 / 1.99%
Volume 17.0K
BIOGB On Other Exchanges
Symbol
Exchange
OTC US
Berlin
Stockholm
OTC US
As of 11:30 AM 09/17/14 All times are local (Market data is delayed by at least 15 minutes).

biogaia ab-b shs (BIOGB) Snapshot

Open
kr174.00
Previous Close
kr175.50
Day High
kr179.00
Day Low
kr174.00
52 Week High
12/30/13 - kr249.46
52 Week Low
08/20/14 - kr161.00
Market Cap
3.1B
Average Volume 10 Days
43.2K
EPS TTM
kr8.38
Shares Outstanding
16.5M
EX-Date
05/7/14
P/E TM
21.4x
Dividend
kr3.35
Dividend Yield
3.91%
Current Stock Chart for BIOGAIA AB-B SHS (BIOGB)

Related News

No related news articles were found.

biogaia ab-b shs (BIOGB) Related Businessweek News

No Related Businessweek News Found

biogaia ab-b shs (BIOGB) Details

BioGaia AB develops, markets, and sells probiotic products with documented health benefits worldwide. The company operates through Finished Consumer Products, Component Products, and Other Products segments. It offers products for the treatment of acute diarrhoea, constipation, helicobacter pylori infection, infant colic, regurgitation, and gingivitis, as well as for digestive and oral health. The company provides BioGaia ProTectis digestive health probiotic drops, as well as BioGaia ProTectis D3 drops with vitamin D3 containing lactobacillus reuteri protectis for children; and BioGaia ProTectis ORS, a probiotic oral rehydration solution with zinc. It also offers BioGaia ProTectis chewable tablet, a dietary supplement containing lactobacillus reuteri protectis, as well as BioGaia ProDentis oral lozenges, a dietary supplement containing lactobacillus reuteri prodentis for adults and children; BioGaia Gastrus, a probiotic supplement that could enhance treatment of Helicobacter pylori infection; and BioGaia ProTectis straw that provides lactobacillus reuteri protectis to various beverages. In addition, the company offers ProDentis oral health tablet for the treatment of periodontal disease and gingivitis; and component products, which are bacterial cultures of lactobacillus reuteri protectis that are used as ingredients in infant formula and cereal products, yoghurt, and other dairy products. Further, it provides animal health products. The company sells its products through pharmacies and related outlets. BioGaia AB was founded in 1990 and is headquartered in Stockholm, Sweden.

91 Employees
Last Reported Date: 08/20/14
Founded in 1990

biogaia ab-b shs (BIOGB) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: kr2.1M
Compensation as of Fiscal Year 2012.

biogaia ab-b shs (BIOGB) Key Developments

BioGaia AB Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months and Parent Earnings Results for the Six Months Ended June 30, 2014

BioGaia AB announced unaudited consolidated earnings results for the second quarter and six months and parent earnings results for the six months ended June 30, 2014. For the six months, on consolidated basis, the company announced net sales of SEK 185,597,000 compared to SEK 163,485,000 for the same period a year ago. Operating profit was SEK 148,712,000 compared to SEK 44,084,000 for the same period a year ago. Profit before tax was SEK 147,074,000 compared to SEK 45,367,000 for the same period a year ago. Profit for the period was SEK 114,512,000 compared to SEK 34,534,000 for the same period a year ago. Profit for the period attributable to owners of the parent company was SEK 114,971,000 compared to SEK 31,994,000 for the same period a year ago. Basic and diluted earnings per share were SEK 6.66 compared to SEK 1.85 for the same period a year ago. Cash flow from operating activities was SEK 136,505,000 compared to SEK 52,332,000 for the same period a year ago. Return on average equity was 37% compared to 8% for the same period a year ago. Investments in property, plant and equipment amounted to SEK 9.5 million compared to SEK 5.2 million for the same period a year ago. Investments in capitalized development expenses amounted to SEK 1.8 million and are attributable to the NEC project compared to nil for the same period a year ago. For the quarter, on consolidated basis, the company announced net sales of SEK 92,379,000 compared to SEK 85,343,000 for the same period a year ago. Operating profit was SEK 24,933,000 compared to SEK 26,330,000 for the same period a year ago. Profit before tax was SEK 22,418,000 compared to SEK 22,664,000 for the same period a year ago. Profit for the period was SEK 17,545,000 compared to SEK 16,857,000 for the same period a year ago. Profit for the period attributable to owners of the parent company was SEK 17,764,000 compared to SEK 15,285,000 for the same period a year ago. Basic and diluted earnings per share were SEK 1.03 compared to SEK 0.89 for the same period a year ago. Cash flow from operating activities was SEK 23,727,000 compared to SEK 28,144,000 for the same period a year ago. For the six months, on parent company basis, the company announced net sales of SEK 177,945,000 compared to SEK 160,421,000 for the same period a year ago. Operating profit was SEK 151,324,000 compared to SEK 41,708,000 for the same period a year ago. Profit before tax was SEK 146,506,000 compared to SEK 37,606,000 for the same period a year ago. Profit for the period was SEK 114,884,000 compared to SEK 28,396,000 for the same period a year ago. Cash flow from operating activities was SEK 135,791,000 compared to SEK 50,989,000 for the same period a year ago.

BioGaia AB, H1 2014 Earnings Call, Aug 20, 2014

BioGaia AB, H1 2014 Earnings Call, Aug 20, 2014

BioGaia Signs New Exclusive Agreement with Nestle Nutrition

BioGaia has extended its global contract with Nestle Nutrition by signing an agreement with the company’s UK infant nutrition business for the exclusive rights to sell BioGaia’s ProTectis Baby Drops in the United Kingdom and Ireland. Launch is planned to take place in the beginning of 2015. Nestle Nutrition UK will market both BioGaia ProTectis Baby Drops, which is BioGaia's biggest product, and BioGaia ProTectis Baby Drops with vitamin D. Both products contain BioGaia's patented and well-documented probiotic strain Lactobacillus reuteri Protectis.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOGB:SS kr179.00 SEK +3.50

BIOGB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BLIS Technologies Ltd $0.02 NZD 0.00
Danone SA €53.47 EUR -0.16
Oragenics Inc $1.31 USD +0.05
Probi AB kr46.20 SEK +0.10
Yakult Honsha Co Ltd ¥5,610 JPY +60.00
View Industry Companies
 

Industry Analysis

BIOGB

Industry Average

Valuation BIOGB Industry Range
Price/Earnings 20.1x
Price/Sales 6.7x
Price/Book 9.3x
Price/Cash Flow 19.2x
TEV/Sales 5.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOGAIA AB-B SHS, please visit www.biogaia.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.